A nonbiologic oral IL-23 inhibitor is more effective and safer than an approved oral JAK inhibitor for moderate-to-severe ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501.

Greek yogurt supplementation post-training significantly reduces inflammation markers in young males, offering insights into ...

Neuroinflammation is linked to a host of detrimental brain disorders, including Alzheimer's and Parkinson's disease. A ...

The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...

Icotrokinra is a first-in-class oral peptide drug that selectively inhibits the IL-23 receptor, disrupting IL-23 signaling ...

Neuroinflammation is linked to a host of detrimental brain disorders, including Alzheimer's and Parkinson's disease. A ...

Tiziana Life Sciences (TLSA) will advance its second asset, a fully human anti-IL-6 receptor monoclonal antibody, TZLS-501. Tiziana will pursue ...

The EMA’s recommendation marks a key step toward expanding treatment access for patients with psoriasis, psoriatic arthritis, ...

Among adults with obesity who lost weight after following a low-calorie diet, weight-loss maintenance with exercise was ...